Synlogic announces synb8802 will advance to phase 1b proof of concept study after proof of mechanism demonstrated in dietary hyperoxaluria

Cambridge, mass., march 24, 2021 /prnewswire/ -- synlogic, inc. (nasdaq: sybx), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that synb8802 has achieved proof of mechanism in a dietary hyperoxaluria study in which healthy volunteers on a high oxalate and low calcium diet were treated with multiple ascending doses of synb8802.
SYBX Ratings Summary
SYBX Quant Ranking